Invention Grant
- Patent Title: Antibody molecules to PD-L1 and uses thereof
-
Application No.: US14881888Application Date: 2015-10-13
-
Publication No.: US09988452B2Publication Date: 2018-06-05
- Inventor: Gordon James Freeman , Arlene Helen Sharpe , Gerhard Johann Frey , Hwai Wen Chang , Jennifer Marie Mataraza , Glenn Dranoff
- Applicant: Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
- Applicant Address: CH Basel US MA Boston US MA Cambridge
- Assignee: Novartis AG,DANA-FARBER CANCER INSTITUTE, INC.,PRESIDENT AND FELLOWS OF HARVARD COLLEGE
- Current Assignee: Novartis AG,DANA-FARBER CANCER INSTITUTE, INC.,PRESIDENT AND FELLOWS OF HARVARD COLLEGE
- Current Assignee Address: CH Basel US MA Boston US MA Cambridge
- Agency: Lando & Anastasi, LLP
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/30 ; C12N15/11 ; C12N5/10 ; A61K45/06 ; A61N5/10 ; G01N33/574 ; A61K39/00
Abstract:
Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
Public/Granted literature
- US20160108123A1 ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF Public/Granted day:2016-04-21
Information query
